Werewolf Therapeutics, Inc. · NASDAQ:HOWL
Werewolf Therapeutics — Technical Presentation (November 2023)
15 slides from Werewolf Therapeutics's technical presentation, Nov 3, 2023
Slide 1: WTX-124 Phase 1/1b Clinical Trial Preliminary Data Overview
SITC 2023 WTX-124 Phase 1/1b Clinical Trial Preliminary Data Overview Investor Webcast November 3, 2023 Shifting the Balance in Cytokine Therapeutics ©2023 WEREWOLF THERAPEUTICS Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Werewolf Therapeutics
Slide 3: WTX-124 preliminary data establish proof of mechanism and proof of concept
WTX-124 Preliminary clinical data* establish proof of mechanism for WTX-124 and proof of concept for INDUKINETM design Dose-escalation ongoing in both monotherapy and pembrolizumab combination Recommended dose for expansion (RDE) and opening of expansion arms expected in 1H 2024 On-going Value Creat
Slide 4: WTX-124 Phase 1/1b Preliminary Data
WTX-124 Phase 1/1b Preliminary Data Preliminary clinical data collected as of October 18, 2023, from an ongoing Phase I/1b study
Slide 5: WTX-124: Expanding the Utility of IL-2 Therapy
The Challenge Deliver the benefits of IL-2 therapy with less toxicity to a broader range of patients Potential WTX-124 Advantages and Opportunity Delivery of IL-2 selectively to the TME to improve the therapeutic index Potential for activity beyond approved indications for rhIL-2 IL-2 therapy with a
Slide 6: Phase 1/1b Trial Design and Details
Determination of monotherapy MTD/RDE Patients with IO sensitive tumor types who have exhausted all SOC options or for whom SOC is not indicated Monotherapy Dose Escalation SITC November 3, 2023: Announced initial safety, tolerability, pharmacokinetics and biomarker data Determination of combination
Slide 7: Study Schema for Monotherapy Dose Escalation Portion of WTX-124x2101
Study Schema for Monotherapy Dose Escalation Portion of WTX-124x2101 1 mg n = 3 3 mg n = 4 6 mg n = 4 12 mg n = 5 TBD Monotherapy Dose Escalation (n≈30) Advanced or metastatic renal cell carcinoma Advanced or metastatic cutaneous melanoma Advanced or metastatic IO sensitive tumor types Recommended d
Slide 8: Patient Demographics from Early Monotherapy Dose Escalation Cohorts
Patient Demographics from Early Monotherapy Dose Escalation Cohorts Enrollment of heavily pretreated patients with tumor types for which immunotherapy, including Proleukin, is indicated Characteristic 1 mg (N=3) 3 mg (N=4) 6 mg (N=4) 12 mg (N=5) Total (N=16) Mean (SD) 70.7 (12.42) 69.5 (7.33) 57.8 (
Slide 9: WTX-124 Generally Well-Tolerated in the Outpatient Setting at Relevant Doses
WTX-124 was Generally Well-Tolerated in the Outpatient Setting at Relevant Doses Sixteen patients in four dose escalation cohorts (1-12 mg IV Q2W) were evaluable for safety Key safety findings to date: All study drug related treatment-emergent adverse events (TEAEs) were mild to moderate in severity
Slide 10: Plasma PK Data Show Extended Half-Life with Low Free IL-2 Exposure
Plasma PK Data Show an Extended WTX-124 Half-Life with Low Free (Active) IL-2 Exposure Preliminary PK data validate INDUKINE design and support improved therapeutic index and safety profile of WTX-124 Cycle 1 PK profiles for WTX-124 and free (active) IL-2 compared to high-dose IL-2 Cmax (mean ± SEM)
Slide 11: Immunofluorescence Staining of Tumor Biopsies from Patients Treated with WTX-124
Immunofluorescence Staining of Tumor Biopsies from Patients Treated with WTX-124 Tumor-specific expansion and activation of CD8 T cells and NK cells differentiate WTX-124 among next-gen IL-2 molecules 65yo F with melanoma (6mg) 50yo F with melanoma (12mg) 61yo F with uveal melanoma (6mg) Pre-treatme
Slide 12: WTX-124 Induced Dose-Dependent Changes in Immune Gene Expression
WTX-124 Induced Dose-Dependent Changes in Immune Gene Expression Consistent with IL-2 Activity in the Tumor Microenvironment Immune genes increased by ≥1.5-fold Number of genes Cohort 1 (1 mg) Cohort 2 (3 mg) Cohort 3 (6 mg) Cohort 4 (12 mg) A B 117 379 A T-cell activation genes increased by ≥2.5-fo
Slide 13: WTX-124 Demonstrated Monotherapy Antitumor Activity in Patients Refractory to ICI Therapy
WTX-124 Demonstrated Monotherapy Antitumor Activity in Patients Refractory to ICI Therapy At 12 mg IV Q2W, WTX-124 shrank treatment-refractory tumor metastatic deposits (3/5 patients); all 12 mg responders remain on study drug Additional evidence of antitumor activity Cohort 4 (12 mg): 72-year-old m
Slide 14: Proof of Mechanism for WTX-124 and Proof of Concept for INDUKINE Design
Proof of Mechanism for WTX-124 and Proof of Concept for INDUKINE Design Preliminary monotherapy dose escalation data from ongoing Phase 1/1b study establish biologic and clinical activity for WTX-124 WTX-124 administered as a monotherapy IV Q2W has been well tolerated and reached exposures associate
Slide 15: Thank You!
THERAPEUTICS Thank You!
Werewolf Therapeutics — Technical Presentation (November 2023) on 6ix